Investor Presentaiton
Appendix (Research and Development)
Product Launch Target (as of May 15, 2023)
Psychiatry &
Neurology
Oncology
Others
FY2025
FY2026
ulotaront
(TAAR1 agonist)
Allogeneic iPS cell-
derived dopaminergic
neural progenitor cells
(DSP-1083)
Allogeneic iPS cell-derived
retinal pigment epithelial
cells (HLCR011)
DSP-5336
(menin and MLL inhibitor)
TP-3654
(PIM kinases inhibitor)
GEMTESAⓇ
(B3-adrenergic receptor agonist)
rodatristat ethyl
(tryptophan hydroxylase inhibitor)
lefamulin
(antimicrobial agent of
pleuromutilin class)
FY2023
FY2024
Schizophrenia
Parkinson's
disease *1
Retinal pigment
epithelium tear*1
Bacterial community-
acquired pneumonia
*1 Launch schedule is based on our goal pending agreement with partners
*2 Premise to utilize an application of accelerated approval program
(Plan to consult with the FDA)
Overactive bladder
with BPH
Acute myeloid
leukemia *2
FY2027
Schizophrenia
Expand
indications
Development
in the U.S
Expand
indications
Acute myeloid
leukemia
Expand
indications
Myelofibrosis
Expand
sales
countries
Overactive
bladder
Pulmonary arterial
hypertension
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 24View entire presentation